rosnilimab
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 22, 2021 (NCT05205070)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095287 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06127043 | Phase 2 | Dec 4, 2023 | AnaptysBio, Inc. |
| NCT06041269 | Phase 2 | Aug 31, 2023 | AnaptysBio, Inc. |
| NCT05205070 | Phase 2 | Dec 22, 2021 | AnaptysBio, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnaptysBio, Inc. | For profit | 3 | 3 | 1 | 2021 |
1 organizations
Page 1 / 1